Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV–hepatitis B virus-infected patients-Reference-Cited by-同舟云学术

Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV–hepatitis B virus-infected patients

Published:2012-05-15 Issue:8 Volume:26 Page:939-949
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Maylin Sarah,Boyd Anders,Lavocat Fabien,Gozlan Joel,Lascoux-Combe Caroline,Miailhes Patrick,Lassel Ludovic,Delaugerre Constance,Girard Pierre-Marie,Zoulim Fabien,Lacombe Karine

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference34 articles.

1. Changes in causes of death among adults infected by HIV between 2000 and 2005: the Mortalite 2000 and 2005 surveys (ANRS EN19 and Mortavic).;Lewden;J Acquir Immune Defic Syndr,2008

2. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.;Papatheodoridis;Lancet Infect Dis,2008

3. EASL clinical practice guidelines: management of chronic hepatitis B.;J Hepatol,2009

4. Chronic hepatitis B.;Lok;Hepatology,2007

5. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study.;Piroth;J Hepatol,2010

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and predictors of HBV functional cure in patients with HIV/HBV coinfection: A retrospective cohort study;Frontiers in Cellular and Infection Microbiology;2023-02-08

2. Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review;Viruses;2021-07-11

3. Incidence and Predictors of Hepatitis B Surface Antigen Clearance in HIV Patients: A Retrospective Multisite Study;Open Forum Infectious Diseases;2021-04-16

4. HIV-HBV Co-infection, Clinical Concerns;Human Viruses: Diseases, Treatments and Vaccines;2021

5. Treatment of HCV, HDV, or HIV Coinfections;Hepatitis B Virus and Liver Disease;2021